SKP2 and chronic myelogenous leukemia, BCR-ABL1 positive: In chronic myeloid leukaemia (CML), Bcr-Abl enhances the phosphorylation stability of Emi1, thereby preventing the degradation of SKP2 and promoting the proliferation of CML cells [12].